Quest Diagnostics Prices $800 Million of Senior Notes

Quest Diagnostics Prices $800 Million of Senior Notes

SECAUCUS, N.J., Dec.

9, 2019 -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information

services, announced today the pricing of a public offering of $800 million aggregate principal amount of its 2.950% senior notes

due 2030 under the Quest Diagnostics' shelf registration statement.

Quest Diagnostics expects

to receive the net offering proceeds upon closing on December 16, 2019, subject to customary closing conditions. The company intends

to use the net proceeds from the offering to repay at maturity or redeem its 4.750% senior notes due 2020 and 2.500% senior notes

due 2020 and for general corporate purposes. This press release is not a notice of redemption. Any notice of redemption will be

made in accordance with the applicable provisions of the indenture governing such notes.

This press release shall

not constitute an offer to sell or a solicitation of an offer to purchase any of these securities and shall not constitute an offer,

solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. This offering

may be made only by means of a prospectus supplement and accompanying base prospectus, copies of which or information concerning

this offering may be obtained by calling J.P. Morgan Securities LLC, collect at (212) 834-4533, Morgan Stanley & Co. LLC, toll-free

at (866) 718-1649 or Wells Fargo Securities, LLC, toll-free at (800) 645-3751.

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health

outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify

and treat disease, inspire healthy behaviors and improve health care management. Quest Diagnostics annually serves one in three

adult Americans and half the physicians and hospitals in the United States, and our 46,000 employees understand that, in the right

hands and with the right context, our diagnostic insights can inspire actions that transform lives.

The statements in this press release which are not historical facts

may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak

only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs

and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties

that may affect the future results of the company include, but are not limited to, adverse results from pending or future government

investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue

recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers,

suppliers or strategic partners and other factors discussed in the company's most recently filed Annual Report on Form 10-K

and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including

those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results"

and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.

CONTACT: Denny Moynihan, Quest Diagnostics (Media): 973-520-2800;

Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900